Product
Tecentriq
2 clinical trials
3 indications
Indication
H3-mutated GliomaIndication
Colon CancerIndication
Stage III Colon CancerClinical trial
A MultIceNTER Phase I Peptide VaCcine Trial to Exploit NeoePitope-Specific T Cells for the Treatment of H3-Mutated Gliomas - (INTERCEPT-H3)Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
Phase II Open-Label Trial of Neoadjuvant Atezolizumab in Combination With CAPEOX for Resectable Non-Metastatic Proficient Mismatch Repair (PMMR) Colon CancerStatus: Not yet recruiting, Estimated PCD: 2026-09-01